Julián Colla (@JulianColla_) header
Julián Colla (@JulianColla_) profile picture

Médico Cardiólogo 🫀🇦🇷- Coordinador Unidad Coronaria La Sagrada Familia / médico de planta Htal Argerich/ miembro SIAC LE

Joined January 2019
Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)Photo by Julián Colla (@JulianColla_)
Trabajo en equipo con @Jessivolpato @luciahelguera Gracias a @CONAREC_ORG por la invitación! @MeliAntoniolli @lucascampanaok
se publicó el libro de “ Electrocardiograma” de @CONAREC_ORG 👏🏻🫶🏼 En 2021 cuando éramos residentes de @ArgerichCardio con mis colegas/amigos @JulianColla_ y @luciahelguera participamos de este proyecto de escribir el capítulo 10. Hoy está al alcance de todos 🫶🏼
5
3
16
2,366
Julián Colla retweeted
Few are bigger evangelists for conduction system pacing than me But. But… These results—despite NEJM publication—do not settle the RV vs LBB pacing. I wrote about it here: medscape.com/viewarticle/bes…
Getting it wrong for many decades. Since the 1950's, pacemaker leads have been placed in the right ventricle. A new randomized trial challenging that dogma found marked superiority of outcomes for pacing from the left bundle branch. nejm.org/doi/full/10.1056/NE…
3
15
1
97
17,877
Julián Colla retweeted
Original Article: Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke (OPTIMAL-STROKE trial) nej.md/3UasT1O #ScientificSessions26 | @AHAScience
2
28
1
114
17,998
Today is #WorldThrombosisDay ❤️ Should clopidogrel replace aspirin for long-term secondary prevention of coronary artery disease? This European Heart Journal Great Debate reviews the contemporary evidence for both strategies and the arguments that may shape future antiplatelet practice ow.ly/91tN50ZVhBq #EHJ #Thrombosis #Aspirin @FeliceGragnano @vlgmrc
1
11
1
36
3,815
Julián Colla retweeted
🫀 Suicide LV after TAVR •Afterload drops → small, hyperdynamic LV obliterates its cavity → dynamic obstruction + shock. •At risk: women, small LV, septal LVH, high EF/gradient. •Treat: fluids, phenylephrine, β-blocker. STOP inotropes.
6
74
1
306
16,345
Julián Colla retweeted
Presented at #ESCCongress: Among 16,808 adults without known cardiovascular disease, silent atherosclerosis was present in 57.1%, was detectable in early adulthood, and became more prevalent and extensive with age in a sex-dependent pattern. Full REACT trial results: nej.md/46gp1hP @escardio
7
170
25
402
94,952
Julián Colla retweeted
🔄 Debemos Deprescribir 88% de los pacientes que inician un betabloqueante no tienen una indicación clara. Revisar y suspender cuando corresponde es parte de la buena práctica. 🧵4/5
2
4
13
584
Clopidogrel monotherapy was associated with lower risks of MACE and major bleeding compared with aspirin monotherapy among stable patients post #PCI, according to a nationwide cohort study published in #JACCAsia. Learn more: bit.ly/4eDjjuo #CardioX @JACCJournals
1
49
2
198
12,680
Julián Colla retweeted
Terapia antitrombótica después de la cirugía de revascularización coronaria (CABG). 💊💥🫀 💊Aspirina: la piedra angular. La aspirina reduce la oclusión de injertos y los eventos CV sin incrementar significativamente el sangrado postoperatorio. ✅Mantener aspirina perioperatorio. ✅Reiniciarla dentro de las primeras 24 horas tras cirugía (idealmente antes de las 6 horas). ✅Continuar de forma indefinida a dosis bajas (75-100 mg/día). 💊💊¿TAP Dual? En pacientes con alto riesgo isquémico y bajo riesgo hemorrágico, puede considerarse aspirina + ticagrelor o clopidogrel durante 12 meses (indicación mas fuerte en SICA que en SCC) para mejorar la permeabilidad de los puentes venosos (reducen MACE pero aumentan 🩸). ✅Reiniciar TAPD tan pronto como el riesgo de sangrado esté controlado. ✅Mantenerla durante 12 meses. ✅Ticagrelor o prasugrel son preferibles a clopidogrel por su mayor reducción de eventos isquémicos y mortalidad. 📄🆓️⤵️ @ESC_Journals 💯 doi.org/10.1093/eurheartj/eh… t.me/medicinainternaconsoque…
51
154
5,745
🫀⚠️ SCOT-HEART changed cardiology with one simple idea: 👉 First scan. Then treat. This is going to generate some hitching to some colleagues within the community 😁. Sorry about that. And 10 years later… the message is even more disruptive. For decades, we built cardiology around: 👉 ischemia 👉 stress tests 👉 flow limitation Find ischemia. Open arteries. Simple. Except… it didn’t reduce hard events consistently. SCOT-HEART helped expose the problem: 👉 Atherosclerosis—not ischemia—is the real disease. At 10 years: 👉 coronary CT guidance reduced: - coronary death - non-fatal MI despite: ❌ NO increase in revascularization Let that sink in. Patients did better NOT because we opened more arteries. They did better because: 👉 we identified plaque 👉 intensified prevention 👉 treated biology earlier The most important number may not be stenosis anymore. It may be: 👉 total plaque burden 👉 plaque phenotype 👉 lipid-rich disease 👉 adverse plaque features The paper says it clearly: Patients with: ⚠️ low-attenuation plaque ⚠️ positive remodeling had dramatically higher event rates. This is the paradigm shift From: ❌ ischemia-centered cardiology To: 👉 plaque-centered prevention And the implications are enormous. Because suddenly: 👉 non-obstructive CAD matters 👉 “normal” stress tests become insufficient 👉 anatomy alone becomes incomplete Even more interesting The next frontier is already here: ⚡ Photon Counting CT ⚡ AI-driven plaque analysis ⚡ Radiomics ⚡ Quantitative phenotyping My take SCOT-HEART did not simply validate coronary CT. It challenged the entire logic of modern cardiology. We used to ask: 👉 “Is this lesion ischemic?” Now the real question is: 👉 “How biologically dangerous is this patient?” Bottom line The future is not: 👉 detect stenosis 👉 react late It is: 👉 detect atherosclerosis early 👉 personalize prevention aggressively ⚡ Because myocardial infarction often starts long before ischemia appears. #SCOTHEART #CCTA #Cardiology #Atherosclerosis #PlaqueImaging #Prevention #PhotonCounting #AI #PrecisionMedicine
4
54
7
181
30,346
Julián Colla retweeted
Un gran honor haber escrito Junto a @JulianColla_ @cardiologiamn y @CardioBornan un capítulo para este gran libro que no tengo dudas será un texto de referencia en #ECG de habla hispana Muchas gracias @adribaran y @distribuna por la invitación 🙌🏼 libreriamedica.com/cardiolog…
4
9
2
36
2,394
Gran iniciativa y herramienta por @atomasyoung 👏👏
¿A cuántos pacientes con ICFEp no estamos diagnosticando y tratando adecuadamente? 🧵 🔗 tomiyoung9.github.io/Calcula…
1
1
89
Julián Colla retweeted
👉 We spend decades arguing about how low to push LDL-C 👆 Almost no one asks the obvious question: 🤔 How much LDL-C did our ancestors actually have? The evidence exists — five independent lines, all converging on the same uncomfortable answer. 1️⃣ The term newborn. Before any dietary or metabolic influence, a healthy neonate arrives with LDL-C of ~30–50 mg/dL. That is the LDLR operating without environmental interference. Everything that rises after birth is acquired. 2️⃣ The Tsimane (Kaplan et al., Lancet 2017) — forager-horticulturalists of the Bolivian Amazon — have a LDL-C between 70 to 90 mg/dL and the lowest prevalence of coronary atherosclerosis ever recorded in any human population. Five times less than the U.S. in adults over 75. And their LDL is rising as roads and processed food arrive. 3️⃣ PCSK9 loss-of-function variants. African American carriers of nonsense mutations (Y142X/C679X, ~2% frequency): −28% LDL-C and −88% CHD risk over 15 years (Cohen et al., NEJM 2006). Homozygous LOF carriers live with LDL-C of ~15–30 mg/dL. Perfectly healthy. Nature already ran the trial. 4️⃣ Evolutionary genetics. Recent positive selection signals exist on gain-of-function PCSK9 variants that raise LDL-C — likely adaptive in food-scarce ancestral environments. Modern hypercholesterolemia is not "normal." It is an ancestral survival advantage turned pathological by evolutionary mismatch. 5️⃣ Great apes in natural habitat: ~40–70 mg/dL LDL-C. Same genome. Different environment. 👆 Bonus — Lp(a). The KIV-2 repeat expansion that raises Lp(a) is a derived, recent variant. Low-Lp(a) alleles are ancestral. Elevated Lp(a) is a textbook antagonistic pleiotropy signal — possibly protective against bleeding early in life, atherogenic over decades 📍The convergent estimate: ancestral LDL-C was ~30–70 mg/dL. 📍An LDL-C of 130 mg/dL is not "normal." It is normal for a Western society in evolutionary mismatch. Targets of <55 mg/dL in high-risk patients — which still feel aggressive to many clinicians — are, ironically, closer to the ancestral phenotype than what we call "normal LDL" in daily practice. 🤔 The question is not "is it safe to lower LDL this much?" The question is: why did we let it rise this high? @society_eas @nationallipid
25
87
10
352
76,204
Julián Colla retweeted
DOCUMENTO AHA 2026 SOBRE DIETA PARA MEJORAR LA SALUD CARDIOVASCULAR Minimizar 🔴Bebidas y alimentos azucaradas🥤🍬 🔴Alimentos con alto contenido de sodio 🧂 🔴Alimentos ultraprocesados 🔴Alcohol 🍷 Vía @CircAHA ahajournals.org/doi/10.1161/…
44
99
4,438
Julián Colla retweeted
🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊 🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications 💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban nejm.org/doi/full/10.1056/NE…
16
280
18
964
367,339
Julián Colla retweeted
Clopidogrel outperformed aspirin in preventing cardiovascular events in patients with coronary artery disease (CAD), showing superior efficacy across both genders, in PANTHER-2 trial. ahajrnls.org/4tLXHTo
4
77
1
255
16,547
Julián Colla retweeted
Muy contento de haber participado de este libro que no tengo dudas que será un texto de referencia para aprender ECG en español Gran equipo con @CardioBornan @cardiologiamn y @JulianColla_ Gracias @adribaran y @distribuna
Simplemente gracias @adribaran por la invitación. Gracias @distribuna por el acompañamiento. Un verdadero placer trabajar junto al gran @gonzaeperez y colegas 🇦🇷 Me lo traigo firmado ✒️ de #SIAC26
20
1
101
9,930
Julián Colla retweeted
📊 Los 5 artículos más leídos de 2025 Los contenidos que marcaron agenda, generaron debate y aportaron evidencia clave para la cardiología de nuestra región. Descubre cuáles fueron los más leídos este año en este hilo 🫀📚 #SIAC #Cardiología #ArtículosCientíficos #Evidencia #SaludCardiovascular
1
11
20
1,042
🔬 La inflamación ya es un factor de riesgo CV tratable ⚠️ hsCRP >2 mg/L predice eventos CV incluso con LDL <70 💊 Colesterol bajo ≠ riesgo bajo si la inflamación persiste 🫀 Medir y tratar la inflamación es prevención cardiovascular moderna ⛓️‍💥doi.org/10.1016:j.jacc.2025.…
4
7
277
1/10 🚨2040: De “Just stent it!” a la era METAL-LESS. 🛑 Serruys et al (EHJ 2025) pronostican el fin de la revascularización mecánica universal. 🚀Nace la “imagenomics” (imaging + omics + IA) p/ decidir entre revascularización farmacológica🆚 mecánica. 🔜El futuro ya empezó
1
3
1
4
431
Revisión para @SIAC_cardio
🩺 Nuevo artículo en #SIAC: “Patrones electrocardiográficos de oclusión coronaria en infarto agudo de miocardio” por el Dr. Julián Colla 🔍 Explora cómo los criterios STEMI/NSTEMI pueden subestimarse, identifica los 11 patrones de “STEMI-equivalentes” y adopta un enfoque más preciso con el modelo OMI/NOMI. ➡️Lee el artículo completo en siacardio.com/patrones-elect…
1
111